MaxCyte (MXCT) (GB:MXCT) has released an update.
MaxCyte, Inc. reported a 32% increase in total revenue to $11.3 million for Q1 2024, buoyed by a substantial 292% rise in Strategic Platform License Program-related revenue, signaling robust growth in their enabling platform technologies for cell therapeutics. Despite overall growth, core business revenue saw a modest increase of 5%. The company affirms its 2024 revenue guidance for core business, with expectations of at least $175 million in cash reserves by year-end.
For further insights into GB:MXCT stock, check out TipRanks’ Stock Analysis page.
